Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|6|929-930

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.6, 2015-06, pp. : 929-930

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Follow-Up of Hydroxyurea-Treated Adults with Sickle Cell Disease

By  

Acta Haematologica, Vol. 125, Iss. 3, 2010-12 ,pp. : 145-152

Karger

Access to resources Recommend Favorite

Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 1956-1961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1862-1864

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 1956-1961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E138-E139

John Wiley & Sons Inc

Access to resources Recommend Favorite